-- Merck (MRK) said Tuesday the US Food and Drug Administration approved the Idvynso drug regimen to treat HIV-1 infection in adults.
Phase 3 trial data supported the approval of Idvynso, according to a statement.
Price: $112.60, Change: $-4.51, Percent Change: -3.85%